rejuvant life tabs

SyndicateRoom co-founder joins First Longevity

Latest articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...
Rejuvant

Tom Britton joins Advisory Panel as plans for Longevity equity funding platform take another step forward.

Longevity.Technology: Just last month we announced the formation of First Longevity’s Advisory Panel, and today we are pleased to welcome its latest member – Tom Britton, the co-founder of venture capital fund SyndicateRoom.

Tom’s experience in creating and growing a hugely successful crowdfunding business will be invaluable as we put plans in place for our international equity funding platform Crowd Longevity.

“I’ve developed a good understanding for the ins and outs of early-stage equity and the factors that play a role in the success of an investment platform,” he says. “Additionally, we’ve worked with a number of clients in life sciences and health-tech which I’ve found fascinating.”


 

Tom co-founded SyndicateRoom in 2012, where he initially headed up the IT and marketing side of the business: “To date, we’ve been involved in circa 300 fundraises.”

 


 

“When the team grew and matured, I turned my attention to developing the product and partnerships we held with VCs and angels,” he says. “To date, we’ve been involved in circa 300 fundraises. Last year we decided to overhaul the business, team, and product to focus on our data-driven fund which is now scaling nicely.”

First Longevity’s Chairman George Sutherland played a key role in helping bring Tom on board.

“I’ve known George for a while and have always respected his advice,” says Tom. “When he explained the direction that CEO Phil Newman wanted to take the business in, it sounded like I could be of use. After speaking with Phil and having the vision fully laid out, I saw an opportunity to be useful but also to gain experience and learn about longevity, an industry that will likely become dominant in life sciences in years to come.”

Elevant

Our recent survey of investors and start-ups also provided some food for thought when it comes to investor appetite in this sector.

“The survey data is supportive of there being appetite for investing in longevity which is encouraging. The investor base, whilst broad, includes a large number of professional individuals who are interested in investing larger amounts into longevity,” says Tom. “It will be interesting to see how we can channel that efficiently.”

So what does he feel are the key challenges facing crowdfunding platforms in today’s competitive landscape?

Elevant

“The name of the game at present is quality,” says Tom. “Generalist platforms struggle to repeat quality and must attempt to cater to so many individuals preferences. Having a specific focus, and being able to continually work with high-quality companies is the only way to compete going forward. I’m excited by the longevity industry and look forward to getting involved.”

Britton becomes the 11th member of First Longevity’s Advisory Panel, which already includes many of the leading investors, researchers and CEOs from the burgeoning longevity sector. Aging Analytics Agency projects that the global longevity economy is projected to reach $27 Trillion in 2026, with the AgeTech segment alone to reach $2.7 Trillion by 2025.

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

FOXO exclusively licenses epigenetic clocks from UCLA

FOXO Technologies' exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer. FOXO Technologies Inc has announced the licence of...

Longevity investment: small sums behind big ideas

Sonia Arrison talks about her journey to becoming an early stage investor and what longevity means to her. While longevity is now seeing increasing interest...

ChromaDex and H&H announce Niagen supply agreement

H&H Group expands Swisse healthy aging product line into growing NAD+ space with Niagen from ChromaDex. Los Angeles-based ChromaDex has announced it entered into a strategic...
Supps report ad middle